After a few days of reflection, Merck & Co has retaliated against an attack on one of its major markets for diabetes treatments. The company has filed suit in the Delhi High Court against Glenmark for allegedly violating patents concerning its diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), on the Indian market.
Scrip was the first to report that Glenmark had launched cut-price versions of Merck's products and that the Indian firm has claimed these were "non-infringing" (
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?